It’s likely that millions of COVID-19 booster shots will be administered in the U.S. in the coming months, but that doesn’t mean companies like Moderna and Pfizer will report an unexpected revenue windfall this year.
It’s likely that millions of COVID-19 booster shots will be administered in the U.S. in the coming months, but that doesn’t mean companies like Moderna and Pfizer will report an unexpected revenue windfall this year.